Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.660 +0.160 (+6.40%)
Official Closing Price Updated: 4:15 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss
Esperion's Q3 2025 shows strong revenue growth beating estimates, but a deeper loss led to a sharp stock sell-off. The company secured key patents and targets profitability in 2026. 
Via Chartmill
Topics Intellectual Property
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For November 6, 2025
 
Via Benzinga
Why Is Esperion Therapeutics Stock Sinking Premarket Today?
Via Stocktwits
Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs
Via Stocktwits
Topics Intellectual Property
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies Global Healthcare Conference - London
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Third Quarter 2025 Financial Results on November 6
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Dow Jumps Over 100 Points; US Crude Oil Inventories Increase
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
These stocks that are showing activity before the opening bell on Wednesday.
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Esperion Announces Pricing of Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Tuesday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Esperion Announces Proposed Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Top 2 Health Care Stocks That May Plunge This Month
 
Via Benzinga
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming September Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.